Navigation Links
PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/11/2007

- Data Presented at 36th Child Neurology Society Annual Meeting -

SOUTH PLAINFIELD, N.J., Oct. 11 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced pharmacokinetic and safety data from a Phase 2 clinical trial of PTC124 in patients with Duchenne muscular dystrophy (DMD) due to a nonsense mutation. The results, which include data from the third and final cohort of the study, show that treatment with PTC124 appeared well tolerated at all three dose levels and target plasma concentrations were achieved at the mid- and high-dose levels. These data were presented today at the 36th Annual Meeting of the Child Neurology Society (CNS) in Quebec City, Canada.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

In the study, patients received 28 days of PTC124 treatment at one of three dose levels. All clinical trial participants are boys with a nonsense mutation in the dystrophin gene, substantially elevated serum creatine kinase levels, and symptoms associated with DMD. The analysis presented today showed that PTC124 appeared well tolerated among the 38 boys included in the study. Adverse events were infrequent, mild to moderate in severity, and did not result in therapy interruptions or discontinuations. There were no concerns based on physical examinations, vital sign measurements, electrocardiograms or laboratory parameters. Compliance with PTC124 treatment was excellent at all three dose levels. Target plasma concentrations associated with activity in a preclinical model of DMD were achieved at the mid- and high-dose levels.

"DMD is a disorder with a significant need for better treatment options and we are encouraged by the results we have seen to date with PTC124," said Brend
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Publicis Groupe customer engagement agency ... and Healthcare Industry Group Leader, has been featured in ... most inspiring people in the life-sciences industry. Those chosen ... development, marketing, technology, creativity, strategy and medicine. ... partner in its leading Rosetta Consulting practice. In 2012, ...
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- ScriptPro has been certified ... its Common Security Framework (CSF). According to ... Manager, "We appreciate this rigorous, top-to-bottom audit. Security-minded ... this certification signifies. Our business partners need to ... CSF CERTIFICATION PROCESS: ScriptPro,s internal security processes and ...
Breaking Medicine Technology:Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2
... Johnson & Johnson (NYSE: JNJ ) today ... & Diagnostics (MD&D) and Sheri McCoy, currently Worldwide Chairman, ... Committee and join William C. Weldon, Chairman of the ... of the Chairman.  Both appointments are effective January 3, ...
... LAKE FOREST, Ill., Dec. 15, 2010 RoundTable ... focused exclusively on the healthcare industry, announced today ... to sell one of its portfolio companies, Clinical ... private investment firm representing Pritzker family interests.  Terms ...
Cached Medicine Technology:Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2
(Date:8/22/2014)... growth factor receptor (EGFR) mutations found in the circulating ... non-small cell lung cancer (NSCLC) patients correlates well with ... EGFR tyrosine kinase inhibitor (TKI) therapy is approved for ... the standard for determining mutation status is with DNA ... or not available. A more abundant and less invasive ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Advancements ... for some clinical applications due to their cost-effectiveness, ... emerging innovations in ultrasound, such as the evolution ... expected to keep the market moving throughout 2014 ... mobility can enhance not only the point-of-care (POC) ...
(Date:8/22/2014)... August 22, 2014 CarePoint Health ... in Internal Medicine, Geriatrics, Hospice and Palliative Care, ... Health Medical Group. Their system welcomes Dr. Reisner ... experienced physicians comprise CarePoint Health Medical Group, a ... Hudson County, representing a wide range of specialties. ...
(Date:8/22/2014)... NJ. August 22, 2014. A new study ... persons with multiple sclerosis (MS) may be able ... The study was epublished ahead of print on ... Helen Genova, Hali Griswold, Nancy D. Chiaravalloti & ... persons with multiple sclerosis doi: 10.3233/NRE-141113). Self-awareness is ...
(Date:8/22/2014)... NEWPORT, RI Newport Hospital has again attained ... Nurses Credentialing Center,s (ANCC) Magnet Recognition Program. Considered ... hospital credentialing program recognizes nursing excellence and professionalism. ... nursing care. The unanimous decision to redesignate Newport ... to rigorous national standards of nursing practice. , ...
Breaking Medicine News(10 mins):Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2
... released the following statement on President Obama,s nomination of ... of Health and Human Services: "Governor Sebelius is ... health care access for children and to provide Kansans ... health care issues and their impact on our workers ...
... Aflac Incorporated (NYSE: AFL ) announced today that ... Annual Institutional Investors Conference. Sr. Vice President of Investor Relations ... is scheduled to make a presentation on March 9 at ... Janke will discuss the company,s outlook for 2009 and its ...
... March 2 Did you know that in ... five times more often and is six times ... are more eye-opening facts to share about this ... at: http://inr.mediaseed.tv/oneClip_C/?feed=pnskfD12vWjRAu2ArGmCrdet11lZRHEf Registered journalists can access video, ...
... A new study in the online issue of ... medications can work well among certain HIV patients who ... at higher risk for cardiovascular disease in part due ... of certain antiretroviral therapies, researchers now have evidence that ...
... week away, study finds, , , MONDAY, March 2 (HealthDay News) ... children with mild persistent asthma begin to show dramatic changes ... March issue of Pediatrics reports that just seven ... for a rural area, airway inflammation went down and lung ...
... cites association on GMPs and adverse event reportingWASHINGTON, ... the U.S. Government Accountability Office (GAO) of a ... supplements, the Natural Products Association (NPA) released the ... Seckman."The Natural Products Association appreciates having the opportunity ...
Cached Medicine News:Health News:Aflac Incorporated To Present at the Raymond James 30th Annual Institutional Investors Conference 2Health News:Largest Study to Date Compares Cholesterol Treatment in HIV Patients & Patients Without HIV Infection 2Health News:Largest Study to Date Compares Cholesterol Treatment in HIV Patients & Patients Without HIV Infection 3Health News:Largest Study to Date Compares Cholesterol Treatment in HIV Patients & Patients Without HIV Infection 4Health News:City Kids Find the Breathin' Is Easier Elsewhere 2Health News:City Kids Find the Breathin' Is Easier Elsewhere 3Health News:Natural Products Association Comments on New GAO Report on Regulation of Dietary Supplements 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: